28.02.2008 22:50:00

Belden Appoints Mary S. McLeod of Pfizer Inc. to Board of Directors

ST. LOUIS, Feb. 28 /PRNewswire-FirstCall/ -- The Board of Directors of Belden has appointed Mary S. McLeod as a Director and member of the Compensation Committee of the board. Ms. McLeod, age 51, is Senior Vice President of Worldwide Human Resources at Pfizer Inc., a post she has held since April 2007. Pfizer is the world's largest global research-based pharmaceutical company. Prior to joining Pfizer, Ms. McLeod was an executive vice president of Korn Consulting Group, a firm specializing in helping companies through large-scale change. Before joining Korn, she led Human Resources for Symbol Technologies and was the head of Human Resources for Charles Schwab, where she was also Chief of Staff for Schwab's chief executive. In addition, she has worked for Cisco Systems and GE. Ms. McLeod has a bachelor's degree from Loyola University and a master's degree from the University of Missouri.

John Stroup, President and Chief Executive Officer of Belden, said, "We are delighted to welcome Mary McLeod to Belden's Board of Directors and the Compensation Committee of the board. She brings valuable experience helping companies achieve their strategic objectives through effective organizational design and compensation systems."

About Belden

Belden is a leader in the design, manufacture, and marketing of signal transmission solutions for data networking and a wide range of specialty electronics markets including entertainment, industrial, security and aerospace applications. To obtain additional information contact Investor Relations at 314-854-8054, or visit our website at http://www.belden.com/.

From: Belden Dee Johnson Director, Investor Relations and Corporate Communications 314.854.8054

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Belden CDT Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Belden CDT Inc. 115,00 -1,71% Belden CDT Inc.
Pfizer Inc. 24,33 -1,00% Pfizer Inc.

Indizes in diesem Artikel

Dow Jones 44 705,53 -0,17%
S&P 500 6 049,88 0,05%
S&P 600 SmallCap 935,46 -0,94%
S&P 100 2 923,16 0,22%
NYSE US 100 17 412,16 0,21%